Millions of people around the world live with the daily impacts of chronic skin conditions like atopic dermatitis (AD) and plaque psoriasis.^i,ii These conditions often present persistent symptoms such as chronic itching, inflammation, and flaking, which can interfere with sleep and subsequently lead to daily disruptions for both patients and their families and caregivers.^iii,iv,v Despite their prevalence, atopic dermatitis and psoriasis continue to represent significant areas of unmet medical need across all age groups.

At Organon, we believe everyone deserves access to treatments that support long-term skin health and everyday well-being.

We are committed to furthering research and building on our legacy portfolio of treatments that address a range of skin conditions, including psoriasis, AD, dermatosis, xerosis and pruritus. Our approach to dermatological care is rooted in real-world impact, and we are investing in therapies that prioritize innovation, accessibility, and clinical relevance.

---

The Impact is More Than Skin Deep

Diagnosing and managing chronic skin conditions like atopic dermatitis and psoriasis is uniquely challenging. Symptoms can vary widely across skin tones, age groups, and individual experience and environments, making personalized care essential.^ii,iii,iv For many patients, it takes a dedicated caregiving team, including dermatologists, primary care providers, and parents to help navigate their daily life.^i,vi

Caregivers to children play a vital role in monitoring flare-ups, coordinating treatments, and offering emotional support. Their involvement becomes even more critical when symptoms interfere with sleep, confidence, or daily activities.^vi

“Finding the right treatment and atopic dermatitis care routine can be difficult because it takes time and persistence,” said Doral Fredericks, Head of Medical and Outcomes Research. “A strong support system not only helps patients stay on track with their care regimen but also empowers them to pursue long-term relief tailored to their unique needs.”

---

---

Healthcare professionals play a central role in guiding patients through the complexities of chronic skin conditions. By fostering shared decision-making, HCPs help ensure that treatment plans reflect each patient’s unique needs, preferences, and lifestyle. As the dermatology landscape evolves, staying informed about emerging therapies is essential.

“A decade ago, options were limited—but today, we’re seeing an exciting expansion of newer therapies that not only manage flares but help prevent them,” said Doral Fredericks. “At Organon, we recognize the vital role dermatologists and dermatology advanced practice providers play in guiding treatment decisions, and we’re committed to supporting their clinical knowledge through robust data, education, and resources.”

Supporting the Full Ecosystem of Stakeholders

Our approach to dermatology is expansive and is deeply rooted in our mission to expand access and improve everyday health. As we grow our presence in dermatology, we remain focused on delivering comprehensive care.

• Patients and Caregivers: Expanding access to education and effective, affordable therapies through initiatives like telehealth, which connect patients with providers offering a full range of treatment options. These virtual options help give busy families a more convenient option to help manage ongoing care needs, and Organon is the first company to offer dermatologic treatment options through partnerships with dermatology-specific telehealth platforms.
• Providers: Providing clinical data and education to support informed care, while committing to inclusive trial design to ensure therapies meet the needs of diverse patient populations.
• Advocates: Working with organizations like the National Eczema Association and National Psoriasis Foundation to offer patients and caregivers a way to share their stories in addition to supporting their initiatives focused on increased patient and provider affordability, equity, and access to care.

Organon is well-positioned to lead in and reshape the future of dermatological care. By leveraging our global capabilities, we aim to expand access to impact therapies, broaden education and support, and help bring relief to millions of patients worldwide impacted by chronic skin conditions.

---

ⁱ Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol. 2021;157(8):940–946. doi:10.1001/jamadermatol.2021.2007

ⁱⁱ International League of Dermatological Societies, Flohr, C., French, L., & Bissonnette, R. (2022). Global Report on Atopic Dermatitis. https://www.eczemacouncil.org/assets/docs/global-report-on-atopic-dermatitis-2022.pdf

ⁱⁱⁱ National Institute of Arthritis and Musculoskeletal and Skin Diseases. AD. Available at: https://www.niams.nih.gov/health-topics/atopic-dermatitis.

^iv National Institute of Arthritis and Musculoskeletal and Skin Diseases. Psoriasis. Available at: Psoriasis Symptoms, Causes, & Risk Factors | NIAMS.

^v Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9. doi: 10.1046/j.1087-0024.2003.09102.x. PMID: 15083780.

^vi Son HK, Kim DH, Lee H, Kim H, Chung K, Kim HS. Family management of childhood atopic dermatitis. J Adv Nurs. 2018 Jun;74(6):1371-1379. doi: 10.1111/jan.13551. Epub 2018 Mar 25. PMID: 29468720.